Synthesis of [1,2,4]Oxadiazolo[4,5-*a*]thiazolo[2,3-*b*]pyrimidin-9(10*H*)-ones via 1,3-Dipolar Cycloaddition of Nitrile Oxide to Thiazolo[3,2-*a*]pyrimidin-3-one Derivatives

Li, Xiaofang(李筱芳) Zheng, Aiting(郑爱庭) Liu, Bin(刘彬) Yu, Xianyong(于贤勇) Yi, Pinggui*(易平贵)

Key Laboratory of Theoretical Chemistry and Molecular Simulation of Ministry of Education & Hunan Province, College Key Laboratory of QSAR/QSPR, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan, Hunan 411201, China

A new class of [1,2,4]oxadiazolo[4,5-a]thiazolo[2,3-b]pyrimidin-9(10*H*)-one was prepared in moderate yields by the reaction of nitrile oxide with 2-arylmethylidene-6,7-dihydro-5*H*-thiazolo[3,2-a]pyrimidin-3-one. The reaction site of dipolarphile is the C=N of thiazolo[3,2-a]pyrimidin-3-one rather than the expected C=C of arylmethylidene. The structures of the products were characterized thoroughly by IR, elemental analysis, MS, and NMR analysis.

Keywords thiazolo[3,2-*a*]pyrimidine, 1,3-dipolar cycloaddition, nitrile oxide, [1,2,4]oxadiazolo[4,5-*a*]thiazolo-[2,3-*b*]pyrimidin-9(10*H*)-one

Introduction

Nitrile oxides are important intermediates as 1,3dipoles in cycloaddition reaction.¹ Reaction of nitrile oxides with alkenes dipolarophiles can obtain isoxazolines which often have important bioactivities.²⁻⁵ the C, N double bond of pyridine, quinoline, isoquinoline and 1,5-benzothiazepine as heterodipolarophile can also react with nitrile oxides to obtain oxadiazoles.^{6,7} Oxadiazoles, the important bioisosters for esters and amides in drug discovery, have been reported to have muscarinic agonist, benzodiazepine receptor agonist, 5-HT agonist, and antirhinoviral activities.⁸⁻¹¹

Thiazolo[3,2-*a*]pyrimidin-3-one derivatives are found to be associated with various biological activities such as antibacterial, antimicrobial and anticancer activities.¹²⁻¹⁴

The incorporation of isoxazoline (or oxadiazole) and thiazolo[3,2-*a*]pyrimidin-3-one into a triheterocyclic system, which we believe could be a useful framework with potential biological activities, has not been investigated yet. In the present work, we wish to report the preliminary results of our attempt to apply the 1,3-dipolar cycloaddition reaction involving nitrile oxide **2** and 2-arylmethylidene-6,7-dihydro-5*H*-thiazolo[3,2-*a*]pyrimidin-3-one **1**, which contain two possible dipolarophile sites (C=N and C=C). Our aim was not only to study the chemoselectivity of the reaction but also to develop a rapid access to new types of poten-

tially bioactive triheterocyclic systems. Such an approach resulted in a synthesis of various [1,2,4]oxadiazolo[4,5-a]thiazolo[2,3-b]pyrimidin-9(10*H*)-ones **4** instead of the spiroisoxazoline **3**, as shown in Scheme 1.

Experimental

Materials and instruments

 1^{14} and 2^{15} were prepared according to the reported procedures. All NMR spectra were recorded on a Bruker AV-II 500 MHz NMR spectrometer, operating at 500 MHz for ¹H, and 125 MHz for ¹³C. TMS was used as an internal reference for ¹H and ¹³C chemical shifts and CDCl₃ was as solvent. Elemental analysis was measured by an Elementar analyzer (varioEL II). MS was conducted by a Finnigan LCQ Advantage MAX mass spectrometer. IR spectra were recorded on a Perkin-Elmer spectrometer (Spectrum One). Melting points were measured by a Yanaco MP500 melting point apparatus and uncorrected.

General procedure for the synthesis of 3-(2,6-dichlorophenyl)-10-arylmethylidene-6,7-dihydro-5*H*-[1,2,4]oxadiazolo[4,5-*a*]thiazolo[2,3-*b*]pyrimidin-9(10*H*)-ones

A mixture of 1 (1 mmol) and 2 (0.19 g, 1 mmol) in dioxane (30 mL) were reflux for 24 h. The solvent was evaporated in vacuum. The residue was purified by



^{*} E-mail: fine_chem@163.com

Received November 13, 2009; revised January 18, 2010; accepted February 5, 2010.

Project supported by the National Natural Science Foundation of China (Nos. 20971041, 20803020, 20772027), and Scientific Research Fund of Hunan Provincial Education Department (Nos. 09B032, 09K081).

Scheme 1



column chromatography on silica gel using petroleum ether and ethyl acetate (V : V=5:1) as eluent to afford

the corresponding 4a-4h. 3-(2,6-Dichlorophenyl)-10-benzylidene-6,7-dihydro-5H-[1,2,4]oxadiazolo[4,5-a]thiazolo[2,3-b]pyrimidin-9(10H)-one (4a) White solid, yield 52%; m.p. 178—180 °C; ¹H NMR (CDCl₃, 500 MHz) δ : 1.99— 2.09 (m, 2H, H_b), 3.05 (ddd, J=1.7, 9.1, 15.4 Hz, 1H, H_a), 3.14 (ddd, $J=1.7, 9.1, 15.4 Hz, 1H, H_a$), 3.41 (ddd, J=1.4, 9.4, 14.2 Hz, 1H, H_c), 4.41 (ddd, J=1.4, 9.4,14.2 Hz, 1H, H_c), 7.35-7.37 (m, 1H), 7.43-7.49 (m, 5H), 7.52–7.54 (m, 2H), 7.72 (s, 1H, H_f); ¹³C NMR (CDCl₃, 125 MHz) *b*: 23.03 (CH₂), 34.17 (CH₂), 36.45 (CH₂), 118.74 (C_d), 122.65 (C_f), 124.01, 128.11, 128.72, 128.81, 128.84, 129.05, 129.85, 132.90, 134.40, 136.18, 136.72, 152.35 (C=N), 163.91 (C=O); IR (KBr) v: 1693.7 (C=O) cm⁻¹; ESI MS m/z: 432 [M+H]⁺. Anal. calcd for C₂₀H₁₅Cl₂N₃O₂S: C 55.56, H 3.50, N 9.72; found C 55.48, H 3.57, N 9.78.

3-(2,6-Dichlorophenyl)-10-(4-methoxybenzylidene)-6,7-dihydro-5H-[1,2,4]oxadiazolo[4,5-a]thiazolo[2,3-b]pyrimidin-9(10H)-one (4b) White solid, yield 58%; m.p. 221–223 °C; ¹H NMR (CDCl₃, 500 MHz) δ: 1.96-2.02 (m, 1H, H_b), 2.04-2.10 (m, 1H, H_b), 3.05 (ddd, J=1.5, 9.1, 15.2 Hz, 1H, H_a), 3.13 (ddd, J=1.5, 9.1, 15.2 Hz, 1H, H_a), 3.40 (ddd, J=1.3, 9.4,14.4 Hz, 1H, H_c), 3.85 (s, 3H, OCH₃), 4.40 (ddd, J=1.3, 9.4, 14.4 Hz, 1H, H_c), 6.96–6.98 (m, 2H), 7.43–7.50 (m, 5H), 7.67 (s, 1H, H_f); ¹³C NMR (CDCl₃, 125 MHz) δ : 23.04 (CH₂), 34.11 (CH₂), 36.44 (CH₂), 55.38 (OCH₃), 118.76 (C_d), 122.70 (C_f), 127.10, 127.95, 128.71, 128.79, 131.58, 132.88, 136.17, 136.70, 152.31 (C=N), 164.14 (C=O); IR (KBr) v: 1693.3 (C=O) cm^{-1} ; ESI MS m/z: 462 $[\text{M}+\text{H}]^+$. Anal. calcd for C₂₁H₁₇Cl₂N₃O₃S: C 54.55, H 3.71, N 9.09; found C 54.40, H 3.88, N 9.18.

3-(2,6-Dichlorophenyl)-10-(4-chlorobenzylidene)-6,7-dihydro-5H-[1,2,4]oxadiazolo[4,5-*a***]thiazolo[2,3***b***]pyrimidin-9(10H)-one (4c) White solid, yield 55%; m.p. 182—183 °C; ¹H NMR (CDCl₃, 500 MHz) \delta: 1.97 —2.09 (m, 2H, H_b), 3.05 (ddd, J=1.3, 9.4, 14.2 Hz, 1H, H_a), 3.16 (ddd, J=1.3, 9.4, 14.2 Hz, 1H, H_a), 3.40 (ddd, J=1.4, 9.4, 14.2 Hz, 1H, H_c), 4.40 (ddd, J=1.4, 9.4,** 14.2 Hz, 1H, H_c), 7.40—7.48 (m, 7H), 7.65 (s, 1H, H_f); ¹³C NMR (CDCl₃, 125 MHz) δ : 22.99 (CH₂), 34.26 (CH₂), 36.46 (CH₂), 118.80 (C_d), 122.55 (C_f), 124.74, 126.66, 128.73, 128.85, 129.08, 130.96, 132.96, 134.81, 136.17, 136.69, 152.39 (C=N), 163.68 (C=O); IR (KBr) v: 1698.8 (C=O) cm⁻¹; ESI MS *m*/*z*: 466 [M+ H]⁺. Anal. calcd for C₂₀H₁₄Cl₃N₃O₂S: C 51.46, H 3.02, N 9.00; found C 51.62, H 3.15, N 8.95.

3-(2,6-Dichlorophenyl)-10-(4-nitrobenzylidene)-6, 7-dihydro-5H-[1,2,4]oxadiazolo[4,5-a]thiazolo[2,3-b]pyrimidin-9(10H)-one (4d) White solid, yield 55%; m.p. 217—219 °C; ¹H NMR (CDCl₃, 500 MHz) δ: 1.99 -2.04 (m, 1H, H_b), 2.10-2.15 (m, 1H, H_b), 3.07 (ddd, J=1.3, 9.1, 15.2 Hz, 1H, H_a), 3.18 (ddd, J=1.3, 9.1, 15.2 Hz, 1H, H_a), 3.42 (ddd, J=1.4, 9.2, 14.0 Hz, 1H, H_c), 4.43 (ddd, J=1.4, 9.2, 14.0 Hz, 1H, H_c), 7.46-7.50 (m, 3H), 7.67 (d, J=8.5 Hz, 2H), 7.73 (s, 1H, H_f), 8.29 (d, J=8.5 Hz, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ : 22.93 (CH₂), 34.49 (CH₂), 36.51 (CH₂), 118.96 (C_d), 122.39 (C_f), 124.09, 125.01, 128.77, 128.87, 129.11, 130.24, 133.07, 136.20, 136.72, 140.80, 147.05, 152.51 (C=N), 163.12 (C=O); IR (KBr) v: 1698.2 (C=O)cm⁻¹; ESI MS m/z: 477 [M+H]⁺. Anal. calcd for C₂₀H₁₄Cl₂N₄O₄S: C 50.33, H 2.96, N 11.74; found C 50.55, H 3.11, N 11.63.

3-(2,6-Dichlorophenyl)-10-(4-fluorobenzylidene)-6,7-dihydro-5H-[1,2,4]oxadiazolo[4,5-*a***]thiazolo[2,3***b***]pyrimidin-9(10H)-one (4e) White solid, yield 48%; m.p. 180—181 °C; ¹H NMR (CDCl₃, 500 MHz) \delta: 1.97 —2.13 (m, 2H, H_b), 3.05 (ddd, J=1.5, 9.0, 15.3 Hz, 1H, H_a), 3.15 (ddd, J=1.5, 9.0, 15.3 Hz, 1H, H_a), 3.41 (ddd, J=1.25, 7.3, 14.2 Hz, 1H, H_c), 4.40 (ddd, J=1.3, 7.3, 14.2 Hz, 1H, H_c), 7.13 (t, J=8.5 Hz, 2H), 7.44—7.53 (m, 5H), 7.67 (s, 1H, H_f); ¹³C NMR (CDCl₃, 125 MHz) \delta: 23.00 (CH₂), 34.21 (CH₂), 36.46 (CH₂), 118.81 (C_d), 122.61 (C_f), 123.71, 123.73, 126.87, 128.73, 128.81, 131.75, 132.93, 136.19, 136.71, 152.37 (C=N), 163.78 (C=O); IR (KBr)** *v***: 1703.7 (C=O) cm⁻¹; ESI MS** *m***/***z***: 450 [M+H]⁺. Anal. calcd for C₂₀H₁₄Cl₂FN₃O₂S: C 53.34, H 3.13, N 9.33; found C 53.20, H 3.29, N 9.24.**

3-(2,6-Dichlorophenyl)-10-(4-methylthiobenzylidene)-6,7-dihydro-5*H***-[1,2,4]oxadiazolo[4,5-***a***]thiazolo-**

Li et al.

[2,3-*b***]pyrimidin-9(10***H***)-one (4f) White solid, yield 55%; m.p. 173—175 °C; ¹H NMR (CDCl₃, 500 MHz) \delta: 1.96—2.03 (m, 1H, H_b), 2.05—2.11 (m, 1H, H_b), 2.52 (s, 3H, SCH₃), 3.05 (ddd,** *J***=1.5, 9.1, 15.2 Hz, 1H, H_a), 3.14 (ddd,** *J***=1.5, 9.1, 15.2 Hz, 1H, H_a), 3.14 (ddd,** *J***=1.5, 9.1, 15.2 Hz, 1H, H_a), 3.41 (ddd,** *J***=1.3, 9.4, 14.4 Hz, 1H, H_c), 4.40 (ddd,** *J***=1.3, 9.4, 14.4 Hz, 1H, H_c), 4.40 (ddd,** *J***=1.3, 9.4, 14.4 Hz, 1H, H_c), 7.27—7.29 (m, 2H), 7.44—7.48 (m, 5H), 7.66 (s, 1H, H_f); ¹³C NMR (CDCl₃, 125 MHz) \delta: 15.17 (SCH₃), 23.04 (CH₂), 34.18 (CH₂), 36.47 (CH₂), 118.79 (C_d), 122.69 (C_f), 122.91, 125.94, 127.62, 128.72, 128.81, 130.21, 130.90, 132.89, 136.21, 136.75, 140.55, 152.34 (C=N), 164.00 (C=O); IR (KBr)** *v***: 1693.9 (C=O) cm⁻¹; ESI MS** *m/z***: 478 [M+H]⁺. Anal. calcd for C₂₁H₁₇Cl₂N₃O₂S₂: C 52.72, H 3.58, N 8.78; found C 52.64, H 3.63, N 8.70.**

3-(2,6-Dichlorophenyl)-10-(2,4-dichlorobenzylidene)-6,7-dihydro-5H-[1,2,4]oxadiazolo[4,5-a]thiazolo-[2,3-b]pyrimidin-9(10H)-one (4g) White solid, yield 50%; m.p. 214—215 °C; ¹H NMR (CDCl₃, 500 MHz) δ: 1.96-2.12 (m, 2H, H_b), 3.05 (ddd, J=1.5, 9.4, 15.2 Hz, 1H, H_a), 3.16 (ddd, J=1.5, 9.4, 15.2 Hz, 1H, H_a), 3.41 $(ddd, J=1.4, 9.4, 14.4 Hz, 1H, H_c), 4.42 (ddd, J=1.4,$ 9.4, 14.4 Hz, 1H, H_c), 7.31-7.34 (m, 1H), 7.44-7.50 (m, 4H), 7.55 (d, J=8.0Hz, 1H), 7.97 (s, 1H, H_f); ¹³C NMR (CDCl₃, 125 MHz) δ: 22.98 (CH₂), 34.35 (CH₂), 36.50 (CH₂), 118.84 (C_d), 122.89 (C_f), 127.34, 127.68, 128.79, 128.86, 129.74, 129. 96, 131.41, 133.05, 135.04, 135.87, 116.19, 136.68, 152.46 (C=N), 163.19 (C=O); IR (KBr) v: 1700.2 (C=O) cm⁻¹; ESI MS m/z: 500 $[M+H]^+$. Anal. calcd for C₂₀H₁₃Cl₄N₃O₂S: C 47.93, H 2.61, N 8.38; found C 48.15, H 2.50, N 8.31.

3-(2,6-Dichlorophenyl)-10-(3,4,5-trimethoxybenzylidene)-6,7-dihydro-5H-[1,2,4]oxadiazolo[4,5-a]thiazolo[2,3-b]pyrimidin-9(10H)-one (4h) White solid, yield 53%; m.p. 186–188 °C; ¹H NMR (CDCl₃, 500 MHz) δ : 1.89–2.10 (m, 2H, H_b), 3.06 (ddd, J=1.4, 9.1, 15.3 Hz, 1H, H_a), 3.15 (ddd, J=1.4, 9.1, 15.3 Hz, 1H, H_a), 3.41 (ddd, J=1.3, 9.4, 14.3 Hz, 1H, H_c), 3.89 (s, 3H, OCH₃), 3.92 (s, 6H, OCH₃), 4.41 (ddd, J=1.3, 9.4, 14.3 Hz, 1H, H_c), 6.78 (s, 2H), 7.44-7.49 (m, 3H), 7.64 (s, 1H, H_f); ¹³C NMR (CDCl₃, 125 MHz) δ : 23.08 (CH₂), 34.17 (CH₂), 36.46 (CH₂), 56.16 (OCH₃), 56.21 (OCH₃), 60.97 (OCH₃), 118.91 (C_d), 122.58 (C_f), 123.12, 128.32, 128.80, 128.84, 130.00, 132.95, 136.21, 136.64, 138.84, 153.34 (C=N), 163.81 (C=O); IR (KBr) v: 1698.5 (C=O) cm⁻¹; ESI MS m/z: 522 [M+ H_{1}^{+} . Anal. calcd for $C_{23}H_{21}Cl_2N_3O_5S$: C 52.88, H 4.05, N 8.04; found C 52.94, H 3.95, N 7.91.

Results and discussion

The structures of compounds **4a**—**4h** were established by different spectroscopic techniques (IR, NMR, and MS) and elemental analysis. The IR spectrum of **4g** displayed $v_{C=0}$ at 1700.2 cm⁻¹. The mass spectrum of **4g** showed a molecular ion peak at m/z 500 ([M+H]⁺) which indicates the addition of nitrile oxide to the 2-(2,4-dichlorobenzylidene)-6,7-dihydro-5*H*-thiazolo[3, 2-*a*]pyrimidin-3-one. The ¹H NMR spectrum of **4g** revealed several multiplets in the range of δ 1.96–4.44 resulting from 1,4,5,6-tetrahydropyrimidine ring for the six protons of three methylenes, several multiplets in the range of δ 7.31–7.57 for aromatic protons. The existence of a singlet at δ 7.97 resulting from benzylidene proton indicates the C=C of benzylidene was not involved in the cycloaddition reaction. Furthermore, the absence of any singlet downfield of δ 6.5 that is assignable for the methine proton of **3g** excluded the presence of product **3g**.^{2,3}

The ${}^{13}C$ NMR spectrum of the product 4g exhibits the presence of three methylene carbons at δ 22.98, 34.35 and 36.50, carbonyl carbons at δ 163.19, benzylidene carbon at δ 122.89 (based on HMQC). The absence of any signal between δ 70–100 that is assignable for the methine and spiro carbon of 3g excluded the presence of 3g.² ¹H-¹³C HMBC spectrum of 4g adds conclusive support for the proposed structure. In the ¹H-¹³C HMBC map of 4g both H_a and H_c correlate with C_d (δ 118.84), H_c and benzylidene proton H_f correlate with a carbonyl carbon $C_g(\delta 163.1)$. The correlation of H_a and C_e (δ 152.46) indicates the carbon atom of nitrile oxide was connected with the nitrogen atom of C = N in 1,4,5,6-tetrahydropyrimidine ring (Figure 1). This kind of regioselectivity was general in the 1,3-dipolar cycloaddition reaction of nitrile oxide and $C = N.^{6,7}$



Figure 1 Part HMBC diagram of 4g.

Conclusion

A novel series of heterocycle compounds, [1,2,4]oxadiazolo[4,5-a]thiazolo[2,3-b]pyrimidin-9(10*H*)-ones, were synthesized by the reaction of nitrile oxide with the C=N of thiazolo[3,2-a]pyrimidine derivatives in moderate yields. The reaction shows high chemoselectivity which only the C=N involved in the cycloaddition and the C=C was inert. This chemoselectivity offers an easy way to synthesize new complicated heterocycles which is difficult to synthesize by common methods.

References

- Caramella, P.; Grunanger, P. In *1,3-Dipolar Cycloaddition Chemistry*, Vol. 1, Ed.: Padwa, A., Wiley, New York, **1984**, p. 291.
- 2 Li, X. F.; Yu, X. Y.; Feng, Y. Q. Chin. J. Chem. 2009, 27, 1531.
- 3 Li, X. F.; Feng, Y. Q.; Xu, M. Acta Cryst. E 2003, 59, 675.

FULL PAPER

- 4 Nicholas, G. M.; Eckman, L. L.; Newton, G. L. Bioorg. Med. Chem. 2003, 11, 601.
- 5 Patrizia, C.; Carmela, D.; Ernesto, F. J. Nat. Prod. 1999, 62, 590.
- 6 Caramella, P.; Bandiera, T.; Albini, F. M.; Gamba, A. Corsaro, A.; Perrini, G. *Tetrahedron* **1988**, *44*, 4917.
- 7 Baouid, A.; Elhazazi, S.; Hasnaoui, A.; Compain, P.; Lavergne, J.-P.; Huet, F. New. J. Chem. 2001, 25, 1479.
- 8 Sako, M.; Oda, S.; Ohara, S.; Hirota, K.; Maki, Y. J. Org. Chem. 1998, 63, 6947.
- 9 Macor, J. E.; Ordway, T.; Smith, R. L.; Verhoest, P. R.;

Mack, R. A. J. Org. Chem. 1996, 61, 3228.

- 10 Romano, M. R.; Lograno, M. D. Eur. J. Pharmacol. 2009, 608, 48.
- 11 Quan, C.; Kurth, M. J. Org. Chem. 2004, 69, 1470.
- 12 Ashok, M.; Holla, B. S.; Kumari, N. S. Eur. J. Med. Chem. 2007, 42, 380.
- 13 Holla, B. S.; Rao, B. S.; Sarojini, B. K.; Akberali, P. M. Eur. J. Med. Chem. 2004, 39, 777.
- 14 Mohan, J.; Kumar, A. Indian J. Heterocycl. Chem. 2002, 11, 325.
- 15 Grundamann, C.; Dean, J. M. J. Org. Chem. 1965, 30, 2810.

(E0911131 Pan, B.)